Brain insulin resistance: A treatment target for cognitive impairment and anhedonia in depression
The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
&NA; Type 2 Diabetes Mellitus (T2DM) and Major Depressive Disorder (MDD) are leading causes of disability worldwide. Indeed, both are costly and burdensome diseases at both individual and socio‐economic levels. Notably, there are similar pathophysiological elements, which might explain the overlap in phenotypic symptoms and the high rate of comorbidity. Brain insulin resistance is a shared metabolic abnormality amongst many individuals with T2DM and MDD. Patients with either or both diseases often exhibit disturbances in cognition and mood, as well as the presence of anhedonia‐like symptoms. However, individuals with T2DM with high glycemic control have reduced cognitive and depressive symptom burden. Based on this evidence, it is possible that repurposing therapies approved for treating insulin resistance may be useful in treating cognitive and anhedonia symptoms in depression. The objective of this review is to discuss the relationship between brain insulin resistance and depression, as well as possible disease modifying therapeutic agents targeting insulin signalling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · cited 1×
“Glucagon-like peptide I (GLP-I) is a gut derived incretin that is beneficial in glycemic control and helps improve insulin sensitivity while reducing appetite and food intake (Drucker and Nauck, 2006; Gault et al., 2013).”
BackgroundRole of Brain Insulin Receptor in Control of Body Weight and Reproduction
Brüning, J. C., Gautam, D., Burks, D. J., Gillette, J., Schubert, M., Orban, P. C., Klein, R., Krone, W., Müller-Wieland, D., & Kahn, C. R. (2000) · Science · doi:10.1126/science.289.5487.2122 · Cited by 2,235
Talbot, K., Wang, H.-Y., Kazi, H., Han, L.-Y., Bakshi, K. P., Stucky, A., Fuino, R. L., Kawaguchi, K. R., Samoyedny, A. J., Wilson, R. S., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59903 · Cited by 1,871
Aguirre, V., Werner, E. D., Giraud, J., Lee, Y. H., Shoelson, S. E., & White, M. F. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m101521200 · Cited by 1,010
Self-citationExercise as a treatment for depression: A meta-analysis
Kvam, S., Kleppe, C. L., Nordhus, I. H., & Hovland, A. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.03.063 · Cited by 837
Exercise for the treatment of depression and anxiety
Carek, P. J., Laibstain, S. E., & Carek, S. M. (2011) · The International Journal of Psychiatry in Medicine · doi:10.2190/pm.41.1.c · Cited by 797 · cited 1×
“Therefore exercise may be implemented as both a preventative measure for depression and as a therapeutic agent (Carek et al., 2011).”
BackgroundTreatment-resistant depression: therapeutic trends, challenges, and future directions
Al-harbi (2012) · Patient Preference and Adherence · doi:10.2147/ppa.s29716 · Cited by 796
The role of insulin receptor signaling in the brain
Plum, L., Schubert, M., & Brüning, J. C. (2005) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2005.01.008 · Cited by 604
Exercise and the Prevention of Depression: Results of the HUNT Cohort Study
Harvey, S. B., Øverland, S., Hatch, S. L., Wessely, S., Mykletun, A., & Hotopf, M. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.16111223 · Cited by 493
The source of cerebral insulin
Banks, W. A. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.02.040 · Cited by 489 · cited 1×
“Insulin can also cross the blood brain barrier (BBB) via a saturable transporter, suggesting insulin in the brain may originate from both brain and pancreatic sources (Banks et al., 2012; Butterfield et al., 2014; Werner and LeRoith, 2014; Banks, 2004).”
Background
Cited by
The menace of obesity to depression and anxiety prevalence
Fulton, S., Décarie-Spain, L., Fioramonti, X., Guiard, B., & Nakajima, S. (2022) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2021.10.005 · Cited by 441
“In turn, a high percentage of patients with depression exhibit insulin resistance [124].”
BackgroundThe brain as an insulin-sensitive metabolic organ
Milstein, J. L., & Ferris, H. A. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101234 · Cited by 259
The Antidepressant Effects of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis
Chen, X., Zhao, P., Wang, W., Guo, L., & Pan, Q. (2024) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2023.08.010 · Cited by 185
Depression, antidepressants, and insulin resistance: which link?
Fanelli, G., & Serretti, A. (2022) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2022.04.011 · Cited by 39
El Massry, M., Alaeddine, L. M., Ali, L., Saad, C., & Eid, A. A. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867327666200908114902 · Cited by 27
Metadata
- Authors
- Hamer, J. A., Testani, D., Mansur, R. B., Lee, Y., Subramaniapillai, M., & McIntyre, R. S.
- Venue
- Experimental Neurology
- Publisher
- Elsevier BV
- Published
- 2019-05
- Volume
- 315
- Pages
- 1-8
- ISSN
- 0014-4886 (ISSN-L)
- OpenAlex
- W2912265551
- Cited by
- 136
- References
- 37
- FWCI
- 9.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Brain insulin resistance: A treatment target for cognitive impairment and anhedonia in depression. https://app.cochat.ai/papers/10.1016/j.expneurol.2019.01.016
- The paper
- Hamer, J. A., Testani, D., Mansur, R. B., Lee, Y., Subramaniapillai, M., & McIntyre, R. S. (2019). Brain insulin resistance: A treatment target for cognitive impairment and anhedonia in depression. Experimental Neurology. https://doi.org/10.1016/j.expneurol.2019.01.016
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.